1SRT Stock Chart & Stats
€195.60
-€8.60(-4.63%)
At close: 4:00 PM EDT
€195.60
-€8.60(-4.63%)
Day’s Range― - ―
52-Week Range€87.00 - €302.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€17.41B
Enterprise Value€19.12B
Total Cash (Recent Filing)€306.90M
Total Debt (Recent Filing)€4.05B
Price to Earnings (P/E)99.6
Beta0.70
Next Earnings
Jan 28, 2027EPS Estimate
1.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.83
Shares Outstanding37,440,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)6.31
Price to Sales (P/S)4.82
P/FCF Ratio79.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.3
Revenue Forecast (FY)€3.73B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables DemandSartorius benefits from repeat consumables demand embedded in biopharmaceutical production and laboratory workflows. Recent double-digit consumables growth supports customer retention, recurring revenue, and a durable installed-base advantage beyond one-time equipment sales.
Broad Growth And Margin ExpansionGrowth across both divisions, combined with higher volumes and operating leverage, indicates improving commercial execution and scalable economics. Sustained margin expansion can strengthen internal funding capacity and reinforce Sartorius's position as customer activity recovers.
Improving Cash Generation And LeverageStronger free cash flow and lower leverage improve financial flexibility while the company continues investing in strategic projects and infrastructure. If maintained, this combination supports debt reduction, resilience, and funding for future product and capacity expansion.
Bears Say
Elevated LeverageMeaningful leverage leaves Sartorius more exposed to operating setbacks and financing burdens than a lightly indebted supplier. Although leverage has improved, the debt load can constrain flexibility for acquisitions, investment, and shareholder returns if conditions weaken.
Uneven Cash ConversionPositive cash flow is not yet consistently converting reported earnings into liquidity. Volatility in conversion can complicate debt reduction and investment planning, making the company's financial improvement less dependable across biopharma and laboratory spending cycles.
Cyclical Equipment ExposureCapital equipment and other non-recurring businesses remain sensitive to customer capacity, utilization, and investment timing. This cyclicality can create uneven revenue and margin progression, even while recurring consumables provide a more stable underlying demand base.
Sartorius News
1SRT FAQ
What was Sartorius AG’s price range in the past 12 months?
Sartorius AG lowest stock price was €87.00 and its highest was €302.00 in the past 12 months.
What is Sartorius AG’s market cap?
Sartorius AG’s market cap is €17.41B.
When is Sartorius AG’s upcoming earnings report date?
Sartorius AG’s upcoming earnings report date is Jan 28, 2027 which is in 95 days.
How were Sartorius AG’s earnings last quarter?
Sartorius AG released its earnings results on Oct 22, 2026. The company reported €1.27 earnings per share for the quarter, beating the consensus estimate of €1.251 by €0.019.
Is Sartorius AG overvalued?
According to Wall Street analysts Sartorius AG’s price is currently Overvalued.
Does Sartorius AG pay dividends?
Sartorius AG does not currently pay dividends.
What is Sartorius AG’s EPS estimate?
Sartorius AG’s EPS estimate is 1.5.
How many shares outstanding does Sartorius AG have?
Sartorius AG has 37,440,000 shares outstanding.
What happened to Sartorius AG’s price movement after its last earnings report?
Sartorius AG reported an EPS of €1.27 in its last earnings report, beating expectations of €1.251. Following the earnings report the stock price went up 2.878%.
Which hedge fund is a major shareholder of Sartorius AG?
Currently, no hedge funds are holding shares in IT:1SRT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sartorius Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.27%
12-Months-Change
Fundamentals
Return on Equity
6.28%
Trailing 12-Months
Asset Growth
0.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sartorius AG
Sartorius AG, founded in Göttingen, Germany in 1870, is a global supplier of advanced bioprocess solutions, laboratory products, and associated services. The company's diverse portfolio encompasses several critical areas: For biosensing and detection, it provides biosensors, compliance instruments, system software, label-free detection technologies, and SPR systems. In cell analysis, Sartorius offers live-cell analysis platforms, flow cytometry systems, and specialized cell analysis reagents and consumables. Its media and reagent segment includes a wide array of formulations for antibody and recombinant protein production, viral vaccines, regenerative medicine, and stem cell cultivation, along with downstream buffers, microcarriers, strong acids, bases, alcohols, and detergents. The company manufactures various bioreactor systems, from multi-parallel and benchtop units to single-use, stainless steel, cell culture, and microbial bioreactors, all supported by dedicated software applications. Its extensive filtration product line features membranes, blotting products, filter papers, and glass and quartz microfibre products, alongside a comprehensive range of filtration devices for ultrafiltration, sterile filtration, harvesting, analytical and diagnostic sample preparation, particle analysis, pharmaceutical applications, protein/DNA concentration, venting, clarification, and membrane chromatography. Sartorius also delivers solutions for process filtration, process chromatography, fluid management, and cutting-edge process analytical technology with data analytics. Complementary laboratory equipment includes industrial microbiology systems, water purification units, precision weighing and pipetting/dispensing systems, OEM components, and centrifuges. Beyond its products, Sartorius provides essential services such as bioprocess development and engineering, protein expression system optimization, media and process development, comprehensive testing, instrument support, and validation. These offerings primarily serve the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industrial sectors across the globe.
Technical Analysis
Evonik
―
GEA Group AG
―
Gerresheimer
―
Pfeiffer Vacuum Technology
―
STRATEC Biomedical
―